Browse News
Filter News
Found 33 articles
-
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
-
SV Health Investors Joins Prilenia Series B as the Company Prepares for ALS and HD Data Readouts in the Next 12 Months
4/12/2022
Prilenia Therapeutics B.V. today announced that it has raised an additional $10 million, bolstering the Series B financing round and bringing total capital raised to date to $144 million.
-
BrainStorm Cell Therapeutics’ NurOwn has taken the amyotrophic lateral sclerosis (ALS) community by storm with new genetic data from its Phase III trial.
-
The Global Huntington’s Disease Treatment Market is Expected to Extend the Market Size at a CAGR of 20% by 2032
2/16/2022
Fact.MR – A Market Research and Competitive Intelligence Provider: The global Huntington’s disease treatment market was expected to attain market value of US$ 360 Mn in 2021.
-
Prilenia Announces Completion of Patient Enrollment Ahead of Schedule in the Pridopidine Arm of the HEALEY ALS Platform Trial
1/5/2022
Prilenia Therapeutics B.V. today announced the completion of participant enrollment in the pridopidine arm of the HEALEY ALS Platform Trial.
-
Prilenia Receives Fast Track Designation for Pridopidine for the Treatment of Huntington’s Disease
11/17/2021
Prilenia Therapeutics B.V. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to pridopidine for development as a potential treatment for Huntington’s Disease (HD).
-
Money on the Move: November 3 – 9
11/10/2021
Investors are lighting up the season already for these biotechs, now flush with cash to spend. Here's who snagged funding this week. -
Prilenia Closes Oversubscribed $43 Million in Series B Financing Round
11/3/2021
Prilenia Therapeutics B.V. today announced that it has raised $43M in an oversubscribed Series B financing round.
-
Prilenia and Huntington Study Group Announce Completion of Patient Enrollment Ahead of Schedule in Global Phase 3 PROOF-HD Huntington’s Disease Clinical Trial
10/20/2021
Prilenia Therapeutics B.V., a clinical stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders, today announced the completion of patient enrollment in the Pridopidine Outcome On Function in Huntington’s Disease (PROOF-HD) global Phase 3 clinical trial.
-
QurAlis' first piece of the puzzle is a protein called stathmin-2, which is encoded by the STMN2 gene.
-
Vaccinex CEO, Dr. Maurice Zauderer, Presented New and Promising Phase 2 SIGNAL Trial Data in a Plenary Session at the European Huntington’s Disease Network Meeting
9/15/2021
Vaccinex, Inc. (Nasdaq: VCNX), today announced that Maurice Zauderer, PhD, Chief Executive Officer, presented new and promising data from continued analysis of final results of the phase 2 SIGNAL Huntington’s Disease Trial at the European Huntington Disease Network Meeting (EHDN2021), which was held September 9-11, 2021.
-
While treatments exist to manage the symptoms of the disease, nothing has proven to be curative – yet. Several biopharma companies are working hard to change that.
-
Oxford Biomedica Appoints Dr. Michael Hayden as Non-Executive Director
7/15/2021
Oxford Biomedica plc, a leading gene and cell therapy group, is pleased to announce that Dr. Michael Hayden has been appointed to the Group’s Board as a Non-Executive Director
-
Prilenia: FDA Grants Orphan Drug Designation for pridopidine for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
7/12/2021
FDA Grants Orphan Drug Designation is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for pridopidine for the treatment of ALS.
-
Prilenia’s Phase 3 Huntington’s Disease Clinical Trial Achieves 50% Enrollment
7/8/2021
Prilenia’s global phase 3 trial in Huntington’s Disease (PROOF-HD) is ahead of schedule after enrolling 50% (240) of target 480 participants
-
Prilenia receives positive EMA opinion on Orphan Drug Designation for pridopidine in ALS
6/29/2021
Prilenia Therapeutics B.V., a clinical stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders, received a positive opinion on European Orphan Drug Designation for pridopidine in Amyotrophic lateral sclerosis (ALS).
-
Incisive Genetics Announces Formation Of Scientific Advisory Board And Appointment Of Dr. Michael R. Hayden As Chairperson
6/28/2021
Incisive Genetics Inc., a privately held biotech company specializing in non-viral delivery methods for targeted gene therapies, announced the formation of its Scientific Advisory Board and the appointment of Dr. Michael R. Hayden as chairperson.
-
Besides providing a sense of hope for children with this devastating disease, this research could offer another clue toward unlocking the mystery behind other forms of ALS.
-
A platform trial is also efficient in that it enables the investigators to share placebo information.
-
Prilenia Achieves 25% Enrollment in its Phase 3 HD Trial and Appoints Dr. Goldberg as CSO
5/13/2021
Prilenia’s global phase 3 trial in Huntington’s Disease (PROOF-HD) has enrolled 120 patients on schedule reaching 25% of its target PROOF-HD is the most advanced clinical trial in HD assessing impact on clinical progression